BioNexus Gene Lab (BGLC) Equity Income (2024 - 2025)
BioNexus Gene Lab recorded quarterly Equity Income of -$28256.0 in Q4 2025, down 219.01% quarter-over-quarter from $23742.0 in Q2 2025, and up 83.72% year-over-year from -$15379.6 in Q4 2024.
BioNexus Gene Lab's Equity Income history runs 2 years deep, the most recent figure standing at -$28256.0 for Q4 2025.
- In Q4 2025, Equity Income rose 83.72% year-over-year to -$28256.0; the TTM figure through Mar 2026 stood at -$4514.0 (up 58.18% YoY), while the FY2024 annual figure was $69476.0, down 77.34% from the prior year.
- Equity Income came in at -$28256.0 for Q4 2025 at BioNexus Gene Lab, down from $23742.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of $88532.0 in Q2 2024 to a low of -$173607.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Linde | 230.79 Bn | 226.84 Bn | 4.26 Bn | 40.00 Mn |
| 2 | Chemical & Mining Co Of Chile | 127.66 Bn | 124.93 Bn | 778.60 Mn | 1.40 Mn |
| 3 | Sherwin Williams | 72.51 Bn | 72.30 Bn | 2.78 Bn | - |
| 4 | Ecolab | 70.96 Bn | 70.34 Bn | 1.85 Bn | - |
| 5 | Air Products & Chemicals | 62.15 Bn | 63.70 Bn | 987.40 Mn | 179.40 Mn |
| 6 | Ppg Industries | 25.04 Bn | 23.57 Bn | 1.66 Bn | - |
| 7 | LyondellBasell Industries | 21.62 Bn | 21.73 Bn | 701.00 Mn | -5.00 Mn |
| 8 | Albemarle | 20.26 Bn | 19.42 Bn | 500.97 Mn | - |
| 9 | DuPont de Nemours | 19.45 Bn | 19.56 Bn | 602.00 Mn | -1.00 Mn |
| 10 | BioNexus Gene Lab | 5.34 Mn | 1.38 Mn | -790.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28,256.00 |
| Jun 30, 2025 | 23,742.00 |
| Mar 31, 2025 | 4,514.00 |
| Dec 31, 2024 | -173,607.00 |
| Sep 30, 2024 | 69,766.00 |
| Jun 30, 2024 | 88,532.00 |
| Mar 31, 2024 | 84,785.00 |